{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immuno-Therapeutic+Agent&page=3",
    "query": {
      "intervention": "Immuno-Therapeutic Agent",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 56,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immuno-Therapeutic+Agent&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immuno-Therapeutic+Agent&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T14:28:43.850Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02771626",
      "title": "Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma (ccRCC)",
        "Melanoma",
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "CB-839",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2016-08-01",
      "completion_date": "2020-04-24",
      "has_results": true,
      "last_update_posted_date": "2023-03-17",
      "last_synced_at": "2026-10-06T14:28:43.850Z",
      "location_count": 17,
      "location_summary": "Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 10 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02771626"
    },
    {
      "nct_id": "NCT05397093",
      "title": "ITIL-306 in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer",
        "Non-small Cell Lung Cancer",
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "ITIL-306",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Instil Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2022-08-24",
      "completion_date": "2026-03-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-10-06T14:28:43.850Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • New York, New York",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05397093"
    },
    {
      "nct_id": "NCT03884556",
      "title": "TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "TTX-030",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "nab paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trishula Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2019-04-10",
      "completion_date": "2023-09-29",
      "has_results": true,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-10-06T14:28:43.850Z",
      "location_count": 16,
      "location_summary": "Orange, California • Sacramento, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03884556"
    },
    {
      "nct_id": "NCT00000822",
      "title": "A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "gp160 Vaccine (Immuno-AG)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Stavudine",
          "type": "DRUG"
        },
        {
          "name": "Didanosine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 46,
      "start_date": null,
      "completion_date": "1999-05",
      "has_results": false,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-10-06T14:28:43.850Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000822"
    },
    {
      "nct_id": "NCT02766699",
      "title": "A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Astrocytoma, Grade IV"
      ],
      "interventions": [
        {
          "name": "EGFR(V)-EDV-Dox",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Engeneic Pty Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2016-10-25",
      "completion_date": "2022-03-30",
      "has_results": false,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-10-06T14:28:43.850Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • New York, New York",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02766699"
    },
    {
      "nct_id": "NCT04020185",
      "title": "Safety and Efficacy Study of IMSA101 in Refractory Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "IMSA101",
          "type": "DRUG"
        },
        {
          "name": "Immune checkpoint inhibitor (ICI)",
          "type": "DRUG"
        },
        {
          "name": "Immuno-oncology (IO) therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ImmuneSensor Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2019-09-23",
      "completion_date": "2023-09-15",
      "has_results": true,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-10-06T14:28:43.850Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04020185"
    },
    {
      "nct_id": "NCT04819373",
      "title": "BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tumor, Solid"
      ],
      "interventions": [
        {
          "name": "BDB001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eikon Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-08-30",
      "completion_date": "2023-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-10-06T14:28:43.850Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04819373"
    },
    {
      "nct_id": "NCT04375150",
      "title": "Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Renal Cell Carcinoma (RCC)"
      ],
      "interventions": [
        {
          "name": "Tyrosine kinase inhibitor (TKI)",
          "type": "DRUG"
        },
        {
          "name": "Immuno-oncology (IO)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 355,
      "start_date": "2019-12-02",
      "completion_date": "2022-10-28",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-06T14:28:43.850Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04375150"
    },
    {
      "nct_id": "NCT04009681",
      "title": "A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastasis"
      ],
      "interventions": [
        {
          "name": "THOR-707",
          "type": "DRUG"
        },
        {
          "name": "Checkpoint inhibitor",
          "type": "DRUG"
        },
        {
          "name": "anti-EGFR antibody",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synthorx, Inc, a Sanofi company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 175,
      "start_date": "2019-06-20",
      "completion_date": "2025-12-02",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-10-06T14:28:43.850Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04009681"
    },
    {
      "nct_id": "NCT04266093",
      "title": "Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cervical Intraepithelial Neoplasia",
        "Cervical Neoplasms",
        "Oropharyngeal Neoplasms",
        "Squamous Intraepithelial Lesions of the Cervix",
        "Hematologic Malignacies"
      ],
      "interventions": [
        {
          "name": "GeneTherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2020-05-08",
      "completion_date": "2050-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-06T14:28:43.850Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04266093"
    }
  ]
}